Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewAZD 3147 is a potent and selective dual mTORC1 and 2 inhibitor (IC50 = 1.5 nM). Exhibits >300-fold selectivity for mTOR over PI 3-kinase isoforms. Orally bioavailable.
AZD 3147 is also offered as part of the Tocriscreen Antiviral Library. 了解 Tocris 化合物库的更多信息。
分子量 | 517.66 |
公式 | C24H31N5O4S2 |
储存 | Store at -20°C |
纯度 | ≥95% (HPLC) |
CAS Number | 1101810-02-9 |
PubChem ID | 25168990 |
InChI Key | JWGVUDPAMQEIJU-INIZCTEOSA-N |
Smiles | OCCNC(NC(C=C1)=CC=C1C2=NC(C3(CC3)S(C4CC4)(=O)=O)=CC(N5[C@@H](C)COCC5)=N2)=S |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Pike et al (2015) Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2. J.Med.Chem. 58 2326 PMID: 25643210
关键词: AZD 3147, AZD 3147 supplier, AZD3147, mTORC1, mTORC2, mammalian, mechanistic, target, of, rapamycin, inhibitors, inhibits, potent, selective, orally, bioavailable, mTOR, 5615, Tocris Bioscience
目前没有该产品的评论。 Be the first to review AZD 3147 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.